Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URLC10, VEGFR1 and VEGFR2 Peptide Vaccine in Refractory Gastric Cancer
NCT00681252Phase 2Completed
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of URLC10, LY6K + VEGFR1 + VEGFR2 and elpamitide in gastric cancer (GC), sponsored by The University of Tokyo. Primary endpoints: Toxicities as assessed by NCI CTCAE version 3 at 2 months and Feasibility as evaluated by RECIST at 2 months. Started May 2008; status: completed.
02
Drugs
URLC10LY6K + VEGFR1 + VEGFR2elpamitide
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00681252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681252.